If You Invested in BIOSTAX CORP (BTAX)

Biostax Corp (BTAX) is a biopharmaceutical company that focuses on immune restoration therapies and healthcare solutions. According to company disclosures, Biostax acquires and develops pharmaceutical and medical technology (MedTech) products with a defined path to market, using a hub-and-spoke development structure. The company has been quoted on the OTC Pink marketplace under the ticker symbol BTAX.

Business model and hub-and-spoke structure

Biostax describes itself as a hub-and-spoke biotech development engine. In this model, the parent company acts as the central hub, providing centralized management and administrative functions. Individual subsidiaries form the spokes, each with a specialized development team focused on specific product pipelines. This structure is intended to support a diversity of product pipelines and, according to the company, to provide revenue opportunities while reducing risk by spreading development efforts across multiple programs.

The company states that it acquires and develops immune restoration pharmaceutical products and MedTech assets that have a clear route to commercialization. Each spoke organization is focused on advancing its own product candidates while drawing on shared resources at the hub level.

Therapeutic focus and immune restoration strategy

Biostax reports that its goal is to develop new therapies that provide disease remission by restoring immune balance in patients with autoimmune, inflammatory, and infectious diseases without suppressing the immune system. The company emphasizes the concept of restoring homeostasis, or balance, to the immune system as a first step toward a potential cure and an approach to improving quality of life in chronic illness associated with immune dysfunction and inflammation.

This immune restoration focus is positioned by Biostax as relevant to a range of conditions where immune dysregulation plays a central role. The company highlights the importance of approaches that aim to rebalance immune responses rather than broadly suppress them.

Pipeline example: JKB-122

Biostax has described a pipeline that includes the drug candidate JKB-122. According to the company, JKB-122 has received FDA authorization to proceed with clinical trials in several indications. These include autoimmune hepatitis in newly diagnosed patients and Phase 2 trials for nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The company has also stated that it plans an Investigational New Drug (IND) filing for JKB-122 as an adjunct therapy in HIV treatment, targeting immune activation and chronic inflammation reduction in non-responders or patients failing current therapies.

These disclosures illustrate how Biostax applies its immune restoration focus to liver disease and infectious disease settings, with an emphasis on modulating immune activity and inflammation.

HIV and substance abuse–related initiatives

Biostax has highlighted activities related to HIV and substance abuse. The company has announced participation in the U.S. Business Action to End HIV Annual Coalition Meeting and a World AIDS Day reception, describing this involvement as part of its commitment to collaborative efforts to combat HIV. Biostax has also indicated that it is dedicated to advancing HIV treatment through research and development efforts that seek to enhance the lives of individuals living with HIV.

In connection with a name and ticker symbol change, Biostax stated that it is pivoting toward the international commercial application of substance abuse solutions. The company has indicated that it aims to address challenges of substance abuse internationally by deploying evidence-based interventions and collaborating with partners, and that it intends to offer products and services designed to support recovery and improve quality of life for affected individuals and communities. Biostax has also referenced its naltrexone technology in combination with a vaccine platform from Immgenuity, Inc. as part of its approach in HIV-related work.

Corporate evolution and trading status

Biostax has reported that its corporate name changed from Immune Therapeutics, Inc. to Biostax, with approval from the State of Florida and FINRA, and that its common stock began trading on the OTC Pink Markets under the ticker symbol BTAX following this change. The company has positioned this rebranding as a milestone in a broader transformation and strategic shift toward substance abuse commercial markets and HIV treatment.

In a subsequent announcement, Biostax stated that its Board of Directors approved, and the company intends to proceed with, the voluntary delisting of its common stock from the OTC Pink marketplace. The company disclosed that a significant portion of shareholders supported the delisting through a Joint Written Consent. Biostax reported that it plans to file a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate the delisting process and, concurrently, a Form 15 to deregister its common stock under the Securities Exchange Act of 1934. The company has stated that, following the effectiveness of the Form 25, its common stock will no longer be traded on the OTC Pink marketplace and that it expects to operate as a private company.

Position in the pharmaceutical preparation manufacturing industry

Within the broader pharmaceutical preparation manufacturing industry, Biostax presents itself as focused on immune restoration and on acquiring and developing assets with a defined path to market. Its disclosures emphasize a pipeline that spans autoimmune, inflammatory, and infectious disease indications, and a business model that relies on multiple specialized subsidiaries supported by a central management hub.

The company’s communications highlight its intention to align its development and commercial efforts with areas such as HIV, liver disease, and substance abuse, where immune function and chronic inflammation are important considerations. Biostax also underscores its interest in partnerships and coalition participation, particularly in the context of HIV-related initiatives.

Company status and investor considerations

According to its own announcements, Biostax is in the process of transitioning away from public trading on the OTC Pink marketplace through a voluntary delisting and deregistration. The company has stated that this decision is part of its long-term strategy and that it expects to benefit from reduced administrative burden and increased flexibility as a private company. For individuals researching BTAX, this means that the symbol has represented Biostax on the OTC Pink market, but the company has indicated that trading on that marketplace will cease following the effectiveness of the Form 25 filing.